Lupin has acquired diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), including the trademark rights associated with these brands. The company has been marketing ONDERO and ONDERO MET since 2015 in the Indian market as part of a comarketing agreement with Boehringer Ingelheim India.
In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future. ONDERO (Linagliptin) and ONDERO MET (Linagliptin + Metformin) are the gold standard in diabetes management. This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
